Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer-Reference-Cited by-同舟云学术

Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer

Published:2022-04-01 Issue:4 Volume:8 Page:537
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Bloomfield Doni¹,D’Andrea Elvira¹,Nagar Sarosh¹,Kesselheim Aaron¹

Affiliation:

1. Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2788563/jamaoncology_bloomfield_2022_oi_210102_1650482106.88716.pdf

Reference57 articles.

1. The US biosimilar market: stunted growth and possible reforms.;Sarpatwari;Clin Pharmacol Ther,2019

2. High generic drug prices and market competition: a retrospective cohort study.;Dave;Ann Intern Med,2017

3. Biosimilars in oncology in the United States: a review.;Nabhan;JAMA Oncol,2018

4. Clinical Development Times for Biosimilars in the United States

5. Why are biosimilars not living up to their promise in the US?;Zhai;AMA J Ethics,2019

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Monoclonal antibody biosimilars for cancer treatment;iScience;2024-06

2. Biosimilar in Lung Cancer;Biosimilars for Cancer Treatment;2024

3. Future Scope of Biosimilars for the Treatment of Various Cancers;Biosimilars for Cancer Treatment;2024

4. Transforming Drug Design: Innovations in Computer-Aided Discovery for Biosimilar Agents;BioMedInformatics;2023-12-08

5. Plain language review: what are biosimilar medicines and how can they be used to treat people with cancer?;Future Oncology;2023-11-27